Recent data suggest that chemotherapeutic agents can be effectively combined with antitumor immune therapies to improve overall survival (OS). However, traditional chemotherapy regimens dosed at maximum tolerated doses (MTD) may be immunosuppressive. It has been suggested that chemotherapeutic agents may have greater and direct effects on immune effector and regulatory cells to stimulate positive antitumor immune responses when applied at lower concentrations or different schedules. This effect may not be restricted to cytotoxic agents such as chemotherapies but also other oncology treatment strategies such as radiotherapy, tyrosine kinase inhibitors and even immunotherapy to avoid development of tolerance or anergy. The recognition that cancer progression is not exclusively due to cancer cell proliferation but is intricately connected to changes in the tumor microenvironment, immune cell infiltration, immune surveillance, overall health of the patient, has changed the outlook of the oncology community.
In this Research Topic we would like to explore novel dosing schedules, combinatorial approaches and modalities for cancer treatment in pre-clinical translational models or clinical research. We welcome Original Research Articles, Reviews and Mini-reviews, including but not limited to the following topics:
1. Mechanism of action and signaling pathways central to the change in conventional dosing paradigms or combinatorial approaches.
2. Identification of gene signature or prognostic markers that predict response to treatment modifications.
3. Identification of new targets based on novel therapeutic approaches.
4. Novel approaches to administering targeted therapies (e.g. tyrosine kinase inhibitors) that synergize well with immunotherapy.
5. Use of pharmacokinetics and pharmacodynamics to inform on modifying dosing schedules of standard of care agents.
Dr. Perera and Dr. Snyder are employees of and own stock in Merck, Inc. All other Topic Editors declare no conflict of interest in relation to the Research Topic theme.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Recent data suggest that chemotherapeutic agents can be effectively combined with antitumor immune therapies to improve overall survival (OS). However, traditional chemotherapy regimens dosed at maximum tolerated doses (MTD) may be immunosuppressive. It has been suggested that chemotherapeutic agents may have greater and direct effects on immune effector and regulatory cells to stimulate positive antitumor immune responses when applied at lower concentrations or different schedules. This effect may not be restricted to cytotoxic agents such as chemotherapies but also other oncology treatment strategies such as radiotherapy, tyrosine kinase inhibitors and even immunotherapy to avoid development of tolerance or anergy. The recognition that cancer progression is not exclusively due to cancer cell proliferation but is intricately connected to changes in the tumor microenvironment, immune cell infiltration, immune surveillance, overall health of the patient, has changed the outlook of the oncology community.
In this Research Topic we would like to explore novel dosing schedules, combinatorial approaches and modalities for cancer treatment in pre-clinical translational models or clinical research. We welcome Original Research Articles, Reviews and Mini-reviews, including but not limited to the following topics:
1. Mechanism of action and signaling pathways central to the change in conventional dosing paradigms or combinatorial approaches.
2. Identification of gene signature or prognostic markers that predict response to treatment modifications.
3. Identification of new targets based on novel therapeutic approaches.
4. Novel approaches to administering targeted therapies (e.g. tyrosine kinase inhibitors) that synergize well with immunotherapy.
5. Use of pharmacokinetics and pharmacodynamics to inform on modifying dosing schedules of standard of care agents.
Dr. Perera and Dr. Snyder are employees of and own stock in Merck, Inc. All other Topic Editors declare no conflict of interest in relation to the Research Topic theme.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
